

Internal Medicine

RESEARCH REVIEW™

Making Education Easy

Issue 69 – 2021

In this issue:

- PPIs ineffective for persistent throat symptoms
- Azithromycin ineffective for COVID-19
- Dexamethasone for chronic subdural haematoma
- Antidepressants for treating back pain and osteoarthritis
- Home insulation and hospital admissions in NZ
- Early high-titre plasma therapy to prevent severe COVID-19
- Efficacy and safety of the mRNA-1273 SARS-COV-2 vaccine
- Rapid deployment of a virtual hospital
- Focused ultrasound subthalamotomy for Parkinson's disease
- Ferric carboxymaltose for iron deficiency at discharge after acute HF

Abbreviations used in this issue

COVID-19 = coronavirus disease 2019

CV = cardiovascular

HF = heart failure

PPI = proton pump inhibitor

RCT = randomised controlled trial

SARS-COV-2 = severe acute respiratory syndrome coronavirus 2

SNRI = serotonin-noradrenaline (norepinephrine) reuptake inhibitor

Welcome to issue 69 of Internal Medicine Research Review.

Several of the research papers selected for this issue focus on the current COVID-19 pandemic: we see convalescent plasma but not azithromycin may be helpful in its treatment, and we also see the results of a phase 3 trial of one of a number of vaccines being developed. This issue also includes NZ research reporting reduced hospital admissions among individuals residing in homes where the EECA subsidy had been used to install insulation. Researchers from the US have also described their experiences running a virtual hospital. There is also a randomised Spanish study reporting that focused ultrasound subthalamotomy in one hemisphere can improve motor features of Parkinson's disease in patients with asymmetric signs.

We hope you enjoy this issue, and we welcome your comments and feedback.

Kind regards

Dr Chris Tofield

Medical Advisor, Research Review

christofield@researchreview.co.nz

Use of proton pump inhibitors to treat persistent throat symptoms

Authors: O'Hara J et al.

Summary: This randomised, placebo-controlled trial examined the use of the PPI lansoprazole for 16 weeks in 346 patients with persistent throat symptoms. There was no significant difference between the lansoprazole and placebo arms for improvement in mean Reflux Symptom Index score at the end of treatment (17.4 vs. 15.6) or for any secondary outcome measure, including Reflux Symptom Index score at 12 months (16.0 vs. 13.6).

Comment: The concept of a link between gastro-oesophageal reflux disease and throat and voice symptoms is entrenched in the clinical community, and persistent throat symptoms are often treated with PPIs. In this UK-based, medium-sized multicentre RCT among patients with persistent throat symptoms, the use of lansoprazole compared with placebo didn't result in improving the persistent throat symptoms. Based on this study, the use of PPIs for persistent throat symptoms couldn't be recommended.

Reference: *BMJ* 2021;372:m4903

[Abstract](#)

Independent commentary by Dr Sisira Jayathissa

Dr Sisira Jayathissa is a General Physician and a Geriatrician. He is also the clinical director of medicine and community health at the Hutt Valley DHB. He is actively involved in both undergraduate and postgraduate medical education in the Wellington region.

For full bio [CLICK HERE](#)



For your patient living with heart failure,
Time is essential.



For the treatment of chronic heart failure
(NYHA Class II-IV) with reduced ejection fraction¹

NYHA - New York Heart Association. Reference 1. ENTRESTO® New Zealand Data Sheet. ENTRESTO® (sacubitril/valsartan) tablets is a prescription medicine which is fully funded under special authority criteria (www.pharmac.govt.nz). Before prescribing please read the Data Sheet available at www.medsafe.govt.nz for information on dosage, contraindications, precautions, interactions and adverse effects. Novartis New Zealand Limited, Auckland. Phone 09 523 8500. NZ-00873 October 2020, TAPS NA12478, BGA201003

For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

a RESEARCH REVIEW™ publication



Jardiance®
(empagliflozin)

FULLY FUNDED
with Special Authority criteria*
February 1st, 2021

NEW. For your patients with type 2 diabetes†

THE POWER TO ACCOMPLISH MORE
Above and beyond glycaemic control^{‡,2}

Click below to download your JARDIANCE resources

PRESCRIBING GUIDE **PATIENT BOOKLET**

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY)

Authors: RECOVERY Collaborative Group

Summary: Patients hospitalised with COVID-19 were randomised to usual standard of care with (n=2582) or without (n=5181) oral or intravenous azithromycin 500mg once daily for 10 days or until discharge as part of the larger open-label RECOVERY trial investigating a range of treatments. The 28-day mortality rate in both the azithromycin and placebo arms was 22% (rate ratio 0.97 [95% CI 0.87, 1.07]), and there was no significant between-group difference for median duration of hospital stay (10 vs. 11 days), the proportion discharged alive within 28 days (rate ratio 1.04 [0.98, 1.10]), or for the proportion meeting the composite endpoint of invasive mechanical ventilation or death among those not on invasive mechanical ventilation at baseline (risk ratio 0.95 [0.87, 1.03]).

Comment: Multiple drug therapies have been studied in COVID-19 without significant benefit. This large RCT comparing azithromycin and placebo failed to show any clinical benefit. The use of azithromycin was based on its perceived clinical benefit related to immunomodulatory actions. Based on these results, azithromycin couldn't be recommended as a treatment for hospitalised patients with COVID-19 not suffering from a bacterial infection.

Reference: *Lancet* 2021;397:605–12

[Abstract](#)

Trial of dexamethasone for chronic subdural hematoma

Authors: Hutchinson PJ et al., for the British Neurosurgical Trainee Research Collaborative and Dex-CSDH Trial Collaborators

Summary: Adults with symptomatic chronic subdural haematoma were randomised to receive oral dexamethasone 8mg twice daily tapered over 2 weeks (evaluable n=341) or placebo (evaluable n=339); 94% of the participants underwent surgical evacuation of their haematoma during the index admission at the discretion of the treating clinician. For the primary outcome, the proportion of dexamethasone recipients with a modified Rankin scale score of 0–3 at 6 months (favourable outcome) was lower than the proportion of placebo recipients (83.9% vs. 90.3% [p=0.01]), but so was the proportion with available data who underwent repeat surgery for haematoma recurrence (1.7% vs. 7.1%). Dexamethasone recipients experienced more adverse events than placebo recipients.

Comment: Glucocorticoids have been used to treat chronic subdural haematoma, but there is limited evidence for effectiveness. In this medium-sized, double-blind RCT, use of a 14-day course of dexamethasone was associated with less favourable outcomes and increased side effects. Dexamethasone couldn't be recommended for routine use in patients with chronic subdural haematoma.

Reference: *N Engl J Med* 2020;383:2616–27

[Abstract](#)

[†]38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).^{‡2}
*JARDIANCE is a funded medicine. Restrictions apply; Pharmaceutical Schedule, Hospital Medicines List. †In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. ‡The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).^{1,2}

1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. *N Engl J Med.* 2015;373(22):2117-2128

JARDIANCE® empagliflozin 10mg, 25mg film coated tablets Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>
INDICATION: *Glycaemic control:* Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy* - When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy* - With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR ≥30mL/min/1.73m² or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR <30mL/min/1.73m² or CrCl <30mL/min). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30mL/min/1.73m²; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged ≥75 years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply; Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (N.Z.) Ltd. Level 3, 2 Osterley Way, Manukau Auckland 2104. TAPS MR7142/PC-NZ-100168 BOE000370



Boehringer Ingelheim (NZ) Ltd.
PO Box 76216 Manukau City,
Auckland 2241. Phone 0800 802 461



Eli Lilly and Company (NZ) Ltd.
PO Box 109197 Newmarket,
Auckland 1149. Phone 0800 500 056
N7BN 042002650642

For more information, please go to <http://www.medsafe.govt.nz>

Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis

Authors: Ferreira GE et al.

Summary: A total of 33 trials were included in this systematic review and meta-analysis to investigate the efficacy and safety of antidepressants for back and osteoarthritis pain compared with placebo. Pain and disability were primary outcomes in the included trials, and these scores were converted to a scale of 0 (no pain or disability) to 100 (worst pain or disability). SNRIs reduced both back pain (mean difference -5.30 [95% CI -7.31, -3.30; moderate certainty) and osteoarthritis pain (-9.72 [-12.75, -6.69]; low certainty) at 3–13 weeks. Very low certainty evidence showed that SNRIs reduced sciatica at ≤2 weeks (-18.60, [95% CI -31.87, -5.33]) but not at 3–13 weeks (-17.50 [-42.90, 7.89]). Tricyclic antidepressants did not reduce sciatica at ≤2 weeks (-7.55 [95% CI -18.25, 3.15]) but did at 3–13 weeks (-15.95 [-31.52, -0.39]) and 3–12 months (-27.0 [-36.11, -17.89]; low-to-very low certainty). SNRIs reduced disability from back pain at 3–13 weeks (-3.55 [95% CI -5.22, -1.88]; moderate certainty) and disability due to osteoarthritis at ≤2 weeks (-5.10 [-7.31, -2.89]; moderate certainty). Pain and disability from back pain were not reduced by tricyclic antidepressants.

Comment: This meta-analysis of RCTs compared the effects of antidepressant drugs with placebo among more than 5000 participants with low back or neck pain, sciatica, or hip or knee osteoarthritis. Drug treatments are largely ineffective for back pain and osteoarthritis, and have the potential for harm. We need to find better strategies to treat patients with these disorders to manage their pain without recourse to the prescribing relatively ineffective medicines.

Reference: *BMJ* 2021;372:m4825

[Abstract](#)

Association between home insulation and hospital admission rates

Authors: Fyfe C et al.

Summary: This NZ quasi-experimental retrospective cohort study used linked datasets to evaluate a national intervention programme to investigate whether retrofitting home insulation would reduce cold-associated hospital admission rates among 994,317 residents of 204,405 houses participating in the EECA's Warm-up New Zealand: Heat Smart retrofit programme (2009–2014). There were 234,873 hospital admissions during the study period, and the rates increased in both the intervention and control groups across all population categories and conditions, with the exception of acute hospital admissions among Pacific peoples (rate ratio 0.94 [95% CI 0.90, 0.98]), and those with asthma (0.92 [0.86, 0.99]), CV disease (0.90 [0.88, 0.93]) or ischaemic heart disease in adults >65 years old (0.79 [0.74, 0.84]). Postintervention increases were lower in the intervention versus the control group (relative rate ratio 0.89 [95% CI 0.88, 0.90]), representing 9.26 fewer hospital admissions per 1000 people. These effects were more pronounced in patients with respiratory disease (relative rate ratio 0.85 [95% CI 0.81, 0.90]), asthma (0.80 [0.70, 0.90]) or ischaemic heart disease in those >65 years old (0.75 [0.66, 0.83]).

Comment: This large NZ-based cohort study provides valuable insight to the value of good public policy into housing stock. Improved insulation of houses was associated with a reduction in hospital admissions mainly related to respiratory problems. The study design creates a chance of significant bias, but they have been minimised. Health professionals need to be aware of living environments of their patients, especially those with respiratory conditions, and must proactively work with other agencies to improve home environments.

Reference: *BMJ* 2020;371:m4571

[Abstract](#)

Early high-titer plasma therapy to prevent severe COVID-19 in older adults

Authors: Libster R et al., for the Fundación INFANT-COVID-19 Group

Summary: Older adults who had presented within 72 hours after mild COVID-19 symptoms started were randomised to receive convalescent plasma with high IgG titres against SARS-COV-2 (n=80) or placebo (n=80) in this trial; enrolment was terminated before planned due to the declining rate of COVID-19 cases in the trial's catchment area. Compared with placebo, a smaller proportion of convalescent plasma recipients developed severe respiratory disease (respiratory rate ≥30 breaths per minute and/or oxygen saturation <93% on ambient air; primary endpoint; 16% vs. 31%; relative risk 0.52 [95% CI 0.29, 0.94]), with a greater effect seen when participants who developed severe respiratory disease before their study infusion were excluded (relative risk 0.40 [0.20, 0.81]). There were no solicited adverse events recorded.

Comment: Using antibody-rich convalescent serum has been used against infections for a long period. The effectiveness of such therapy in COVID-19 is starting to emerge. In this small RCT, the use of convalescent plasma with high titres of antibodies against SARS-COV-2 in infected patients administered within 72 hours after the onset of symptoms reduced the risk of progression to severe respiratory disease. The authors didn't assess the long-term outcomes. Early administration of antibody-rich convalescent plasma seems to be a reasonable treatment option in patients with COVID-19.

Reference: *N Engl J Med* 2021;384:610–8

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#)

CLICK HERE to read our latest Product review on MF59®-Adjuvanted Inactivated Quadrivalent Influenza Vaccine (Fluad® Quad) for Older Adults

The review summarises data relevant to the use of the MF59-Adjuvanted inactivated quadrivalent influenza vaccine (Fluad® Quad) for the prevention of seasonal influenza in adults aged ≥65 years, against the background of a high burden of disease in older adults and factors that can reduce vaccine effectiveness. The effects of Covid-19 on influenza and influenza vaccination are also discussed.



Rotorua GP CME
General Practice Conference & Medical Exhibition

10-13 JUNE 2021
ENERGY EVENTS CENTRE
ROTORUA

[gpcme.co.nz](#)

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Authors: Baden LR et al., for the COVE Study Group

Summary: Individuals deemed to be at high risk for SARS-CoV-2 infection or its complications were randomised to receive two intramuscular injections of the mRNA-1273 vaccine 100µg against SARS-CoV-2 (n=15,210) or placebo (n=15,210) 28 days apart in this phase 3 trial, with >96% of participants receiving both their injections, and 2.2% having serological and/or virological evidence of SARS-CoV-2 infection at baseline. Compared with placebo, symptomatic COVID-19 illness occurred in significantly fewer mRNA-1273 vaccine recipients (3.3 vs. 56.5 per 1000 person-years,) providing vaccine efficacy of 94.1% (p<0.001); the efficacy of the vaccine was similar across key secondary analyses, including assessment 14 days after the first dose, inclusion of participants with evidence of SARS-CoV-2 infection at baseline, and in participants aged ≥65 years. All 30 participants who developed severe COVID-19, including one fatality, were from the placebo group. The mRNA-1273 vaccine was associated with more moderate, transient reactogenicity, but serious adverse events were rare and occurred at similar incidences between the two groups.

Comment: This large phase 3 RCT was conducted to determine the efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine (Moderna) compared with placebo. The results showed good short-term vaccine efficacy. However, questions remain unanswered on long-term efficacy, the potential for unknown side effects, efficacy against major mutant viruses and the ability to protect against asymptomatic infections. However, the development of a number of effective vaccines over a short period should be applauded.

Reference: *N Engl J Med* 2021;384:403–16

[Abstract](#)

Insights from rapid deployment of a 'virtual hospital' as standard care during the COVID-19 pandemic

Authors: Sitamagari K et al.

Summary: The development and rapid deployment of a virtual hospital programme (Atrium Health hospital at home) within a large US healthcare system was described. The programme comprised proactive home monitoring and hospital-level care via a virtual observation unit and a virtual acute care unit in the home settings of 1477 eligible patients with COVID-19. The median 'length of stay' for the patients was 11 days. Among 1293 patients (88%) who received care in the virtual observation unit only, 40 (3%) required inpatient hospitalisation, and of these, 40% were admitted to an ICU, 18% required ventilator support and 5% died during their hospital admission. Among 184 patients (12%) admitted to the virtual acute care unit, 11% required intravenous fluids, 9% received antibiotics, 22% required respiratory inhaler or nebuliser treatments and 22% received supplemental oxygen. Of the 24 patients (13%) from this group who needed to be admitted to a conventional hospital, 42% required ICU admission, 3% required a ventilator and none died.

Comment: Telehealth has become increasingly important during this century, especially during the pandemic. There have been barriers to telehealth, including the inability to have proper consultations. This study showed the ability of a robust telehealth system combined with backup for managing health issues in a selected patient population. As many other medical interventions, telehealth needs to evolve with good clinical governance to be safe and effective.

Reference: *Ann Intern Med* 2021;174:192–9

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**

Randomized trial of focused ultrasound subthalamotomy for Parkinson's disease

Authors: Martínez-Fernández R et al.

Summary: This Spanish study investigated the efficacy of focused ultrasound subthalamotomy in patients with markedly asymmetric Parkinson's disease who had motor signs not fully controlled by medication or who were ineligible for deep-brain stimulation. The participants were randomised to undergo MRI-guided focused ultrasound subthalamotomy on the side opposite their main motor signs (n=27) or a sham procedure (n=13). The primary efficacy outcome of mean Movement Disorder Society – Unified Parkinson's Disease Rating Scale part III score for the more affected body side in the off-medication state decreased from 19.9 at baseline to 9.9 at 4 months in the active-treatment group and from 18.7 to 17.1 in the control group (between-group difference, 8.1 points [p<0.001]). Adverse events that persisted at 4 months in the focused ultrasound subthalamotomy group were dyskinesia in the off-medication state (n=3) and on-medication state (n=1), weakness on the treated side (n=2), speech disturbance (n=3), facial weakness (n=1) and gait disturbance (n=2).

Comment: This small two-centre, sham-controlled RCT involving relatively young Parkinson's disease patients showed focused ultrasound subthalamotomy has resulted in improved motor features of Parkinson's disease on the more affected side. However, adverse events were frequent and persisted in several patients. Given the young age of the patients and irreversible nature of ultrasound-related damage, this new treatment method needs to be compared against other invasive treatments prior to being accepted into regular clinical practice.

Reference: *N Engl J Med* 2020;383:2501–13

[Abstract](#)

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure

Authors: Ponikowski P et al., on behalf of the AFFIRM-AHF Investigators

Summary: Adults hospitalised for acute HF who were iron deficient and had a left ventricular ejection fraction of <50% were randomised to receive intravenous ferric carboxymaltose (dose set according to extent of iron deficiency; evaluable n=558) or placebo (evaluable n=550) for ≤24 weeks in this trial. The difference between the ferric carboxymaltose and placebo groups for primary outcome events (composite of total hospitalisations for HF and CV-related death during the 52-week postrandomisation period) failed to reach statistical significance (57.2 vs. 72.5 per 100 patient-years [p=0.059]), with no significant between-group difference in the risk of CV-related death (hazard ratio 0.96 [95% CI 0.70, 1.32]), but significantly lower risks of hospitalisation for HF (rate ratio 0.74 [0.58, 0.94]) and a composite of first HF hospitalisation or CV-related death (32% vs. 38%; hazard ratio 0.80 [0.66, 0.98]). The respective serious adverse event rates in the ferric carboxymaltose and placebo arms were 45% and 51%.

Comment: In this large double-blind RCT among patients with iron deficiency, and who had stabilised after an episode of acute HF, treatment with ferric carboxymaltose was safe and reduced the risk of HF hospitalisation without an effect on the risk of CV death and side effects. Interestingly, this benefit was shown in the patients without laboratory-confirmed anaemia. There appeared to be no attempt to address the cause of iron deficiency. All these factors need to be considered prior to considering ferric carboxymaltose treatment for all patients with systolic HF and biochemical iron deficiency.

Reference: *Lancet* 2020;396:1895–904

[Abstract](#)

[CLICK HERE](#)

to read previous issues of Internal Medicine Research Review

RACP MyCPD Program participants can claim one credit per hour (maximum of 60 credits per year) for reading and evaluating Research Reviews.

FOR MORE INFORMATION [CLICK HERE](#)